Viking Therapeutics Advances Weight-Loss Drug into Final Clinical Trials

Viking Therapeutics US92686J1060

Biopharmaceutical company Viking Therapeutics has moved its lead obesity treatment candidate into the final stage of clinical development, following the publication of robust mid-stage trial data. The firm is now conducting two major Phase 3 studies, with investor focus squarely on the progress of this regulatory pathway.

On January 12, 2026, the medical journal Obesity published detailed results from Viking’s Phase 2 VENTURE study of VK2735. The data demonstrated that patients achieved an average weight reduction of up to 14.7% after just 13 weeks of treatment. Notably, the weight-loss curve showed no signs of plateauing at that point, suggesting potential for greater efficacy with longer-term use.